-
摘要: 随着多种靶向药物的问世，急性髓系白血病(acute myeloid leukemia，AML)逐渐进入靶向治疗时代。其中索拉非尼作为一种以靶向FLT3-ITD为主的多激酶抑制剂，在AML治疗中得到广泛应用，主要用于FLT3-ITD+AML的治疗，特别是移植后的维持治疗。另外，鉴于索拉非尼的多激酶抑制特征，也有不少研究尝试将其用于FLT3野生组AML的治疗。本文综述了索拉非尼在AML中的治疗应用及相关研究进展。Abstract: With the emergence of a variety of targeted drugs, acute myeloid leukemia(AML) has gradually entered an era of targeted therapy. As a multikinase inhibitor, mainly targeting FLT3-ITD, sorafenib is widely used in the treatment of AML, and it is mainly used for FLT3-ITD mutated AML, especially for the maintenance therapy after allogeneic hematopoietic stem cell transplantation. Besides, based on its multikinase inhibition, many studies have also tried to use sorafenib for the treatment of AML with FLT3-WT. Therefore, this review summarizes the therapeutic application and the progress of sorafenib in AML with FLT3-ITD mutation or FLT3-WT.
-
Key words:
- acute myeloid leukemia /
- sorafenib
-
-
[1] Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022, 140(12): 1345-1377. doi: 10.1182/blood.2022016867
[2] National Comprehensive Cancer Network. Acute Myeloid Leukemia(version 3)[EB/OL].
https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf (2023).[3] 中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)[J]. 中华血液学杂志, 2023, 44(9): 705-712.
[4] Antar AI, Otrock ZK, Jabbour E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions[J]. Leukemia, 2020, 34: 682-696. doi: 10.1038/s41375-019-0694-3
[5] Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia[J]. J Natl Cancer Inst, 2008, 100(3): 184-198. doi: 10.1093/jnci/djm328
[6] Borthakur G, Kantarjian H, Ravandi F, et al. Phase Ⅰ study of sorafenib in patients with refractory or relapsed acute leukemias[J]. Haematologica, 2011, 96(1): 62-68. doi: 10.3324/haematol.2010.030452
[7] Frohling S, Schlenk RF, Breitruck J, et al. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults(16 to 60 years)with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group[J]. Blood, 2002, 100: 4372-4380. doi: 10.1182/blood-2002-05-1440
[8] Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation[J]. N Engl J Med, 2017, 377(5): 454-464. doi: 10.1056/NEJMoa1614359
[9] Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia(QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10388): 1571-1583. doi: 10.1016/S0140-6736(23)00464-6
[10] Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML[J]. N Engl J Med, 2019, 381(18): 1728-1740. doi: 10.1056/NEJMoa1902688
[11] Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia(QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 984-997. doi: 10.1016/S1470-2045(19)30150-0
[12] Chen YB, Li S, Lane AA, et al. Phase Ⅰ trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia[J]. Biol Blood Marrow Transplant, 2014, 20(12): 2042-2048. doi: 10.1016/j.bbmt.2014.09.007
[13] Xuan L, Wang Y, Chen J, et al. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(8): 1674-1681. doi: 10.1016/j.bbmt.2019.04.018
[14] Burchert A, Bug G, Fritz LV, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation(SORMAIN)[J]. J Clin Oncol, 2020, 38(26): 2993-3002. doi: 10.1200/JCO.19.03345
[15] Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial[J]. Lancet Oncol, 2020, 21(9): 1201-1212. doi: 10.1016/S1470-2045(20)30455-1
[16] Xuan L, Wang Y, Yang K, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial[J]. Lancet Haematol, 2023, 10(8): e600-e611. doi: 10.1016/S2352-3026(23)00117-5
[17] Pratz KW, Cho E, Levis MJ, et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias[J]. Leukemia, 2010, 24(8): 1437-1444. doi: 10.1038/leu.2010.132
[18] Ravandi F, Cortes JE, Jones D, et al. Phase Ⅰ/Ⅱ study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia[J]. J Clin Oncol, 2010, 28: 1856-1862. doi: 10.1200/JCO.2009.25.4888
[19] Sasaki K, Kantarjian HM, Kadia T, et al. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia[J]. Cancer, 2019, 125(21): 3755-3766. doi: 10.1002/cncr.32387
[20] Chen F, Sun J, Yin C, et al. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation[J]. Bone Marrow Transplant, 2020, 55(4): 740-748. doi: 10.1038/s41409-019-0721-z
[21] Xuan L, Wang Y, Chen J, et al. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(8): 1674-1681. doi: 10.1016/j.bbmt.2019.04.018
[22] Xuan L, Wang Y, Huang F, et al. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation[J]. Cancer, 2018, 124(9): 1954-1963. doi: 10.1002/cncr.31295
[23] Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standardtherapy in patients aged 60 years or younger with newly diag-nosed acute myeloid leukaemia(SORAML): a multicentre, phase 2, randomised controlled trial[J]. Lancet Oncol, 2015, 16: 1691-1699. doi: 10.1016/S1470-2045(15)00362-9
[24] Röllig C, Serve H, Noppeney R, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial[J]. Leukemia, 2021, 35(9): 2517-2525. doi: 10.1038/s41375-021-01148-x
[25] Pollard JA, Alonzo TA, Gerbing R, et al. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031[J]. J Clin Oncol, 2022, 40(18): 2023-2035. doi: 10.1200/JCO.21.01612
[26] Loo S, Roberts AW, Anstee NS, et al. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG[J]. Blood, 2023, 142(23): 1960-1971. doi: 10.1182/blood.2023020301
[27] Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial[J]. J Clin Oncol, 2013;31: 3110-3118. doi: 10.1200/JCO.2012.46.4990
[28] Daver N, Perl AE, Maly J, et al. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia[J]. J Clin Oncol, 2022, 40(35): 4048-4059. doi: 10.1200/JCO.22.00602
[29] Short NJ, Daver N, Dinardo CD, et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML[J]. J Clin Oncol, 2024, 26: JCO2301911.
[30] Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation[J]. Blood, 2013, 121: 4655-4662. doi: 10.1182/blood-2013-01-480228
[31] Zhang C, Lam SSY, Leung GMK, et al. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3[J]. Cancer, 2020, 126(2): 344-353. doi: 10.1002/cncr.32534
[32] 张钰, 宣丽, 范志平, 等. 索拉非尼作为挽救性治疗在难治复发性FLT3突变阳性急性髓系白血病中的临床应用研究[J]. 中华血液学杂志, 2016, 37(4): 292-296.
[33] Yu S, Zhang Y, Yu G, et al. Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study[J]. J Intern Med, 2024, 295(2): 216-228. doi: 10.1111/joim.13738
[34] Shao R, Zhang Y, He J, et al. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study[J]. Signal Transduct Target Ther, 2023, 8(1): 348. doi: 10.1038/s41392-023-01614-1
[35] Mathew NR, Baumgartner F, Braun L, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells[J]. Nat Med, 2018, 24: 282-291. doi: 10.1038/nm.4484
[36] Romero D. Sorafenib prevents AML relapse after allo-HSCT[J]. Nat Rev Clin Oncol, 2020, 17(10): 591. doi: 10.1038/s41571-020-00431-7
[37] Bazarbachi A, Labopin M, Battipaglia G, et al. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party[J]. Haematologica, 2019, 104: e398-e401. doi: 10.3324/haematol.2018.211615
[38] Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J]. Haematologica, 2020, 105(6): 1507-1516. doi: 10.3324/haematol.2019.243410
[39] Halpern AB, Rodríguez-Arbolí E, Othus M, et al. Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML[J]. Blood Adv, 2023, 7(17): 4950-4961. doi: 10.1182/bloodadvances.2023010392
[40] Yang N, Gu Z, Liu Z, et al. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/Refractory Acute Myeloid Leukemia[J]. Anticancer Agents Med Chem, 2018, 18(10): 1489-1494.
[41] Chen X, Huang J, Xu N, at al. A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia[J]. Cancer, 2022, 128(11): 2138-2147. doi: 10.1002/cncr.34182
[42] Liu S, Wang Y. Diagnosis and management of adult central nervous system leukemia[J]. Blood Sci, 2023, 5(3): 141-149. doi: 10.1097/BS9.0000000000000162
[43] Massard C, Zonierek J, Gross-Goupil M, et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib[J]. Ann Oncol, 2010, 21: 1027-1031. doi: 10.1093/annonc/mdp411
[44] Sprinzl MF, Reisinger F, Puschnik A, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells[J]. Hepatology, 2013, 57: 2358-2368. doi: 10.1002/hep.26328
[45] Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec[J]. Proc Natl Acad Sci U S A, 2005, 102(4): 1104-1109. doi: 10.1073/pnas.0408831102
[46] Joshi SK, Nechiporuk T, Bottomly D, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance[J]. Cancer Cell, 2021, 39(7): 999-1014. doi: 10.1016/j.ccell.2021.06.003
[47] Yang T, Hu M, Qi W, et al. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms[J]. J Med Chem, 2019, 62(22): 10305-10320. doi: 10.1021/acs.jmedchem.9b01348
[48] Xu D, Chen Y, Yang Y, et al. Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation[J]. J Transl Med, 2022, 20(1): 300. doi: 10.1186/s12967-022-03498-1
[49] Zhang W, Yu G, Zhang H, et al. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy[J]. Haematologica, 2023, 108(6): 1500-1514.
[50] Xu X, Ma W, Qiu G, et al. Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2[J]. Biology(Basel), 2023, 12(10): 1337.
[51] 张钰, 邵若洋, 刘启发. FLT3突变急性髓系白血病的全程管理[J]. 临床血液学杂志, 2023, 36(5): 303-308. doi: 10.13201/j.issn.1004-2806.2023.05.002
-
计量
- 文章访问数: 529
- PDF下载数: 29
- 施引文献: 0
下载: